Cargando…

Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation

OBJECTIVE: Electronic healthcare databases (EHDs) are useful tools for drug development and safety evaluation but their heterogeneity of structure, validity and access across Europe complicates the conduct of multidatabase studies. In this paper, we provide insight into available EHDs to support reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacurariu, Alexandra, Plueschke, Kelly, McGettigan, Patricia, Morales, Daniel R, Slattery, Jim, Vogl, Dagmar, Goedecke, Thomas, Kurz, Xavier, Cave, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129090/
https://www.ncbi.nlm.nih.gov/pubmed/30185579
http://dx.doi.org/10.1136/bmjopen-2018-023090
_version_ 1783353753562251264
author Pacurariu, Alexandra
Plueschke, Kelly
McGettigan, Patricia
Morales, Daniel R
Slattery, Jim
Vogl, Dagmar
Goedecke, Thomas
Kurz, Xavier
Cave, Alison
author_facet Pacurariu, Alexandra
Plueschke, Kelly
McGettigan, Patricia
Morales, Daniel R
Slattery, Jim
Vogl, Dagmar
Goedecke, Thomas
Kurz, Xavier
Cave, Alison
author_sort Pacurariu, Alexandra
collection PubMed
description OBJECTIVE: Electronic healthcare databases (EHDs) are useful tools for drug development and safety evaluation but their heterogeneity of structure, validity and access across Europe complicates the conduct of multidatabase studies. In this paper, we provide insight into available EHDs to support regulatory decisions on medicines. METHODS: EHDs were identified from publicly available information from the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance resources database, textbooks and web-based searches. Databases were selected using criteria related to accessibility, longitudinal dimension, recording of exposure and outcomes, and generalisability. Extracted information was verified with the database owners. RESULTS: A total of 34 EHDs were selected after applying key criteria relevant for regulatory purposes. The most represented regions were Northern, Central and Western Europe. The most frequent types of data source were electronic medical records (44.1%) and record linkage systems (29.4%). The median number of patients registered in the 34 data sources was 5 million (range 0.07–15 million) while the median time covered by a database was 18.5 years. Paediatric patients were included in 32 databases (94%). Completeness of information on drug exposure was variable. Published validation studies were found for only 17 databases (50%). Some level of access exists for 25 databases (73.5%), and 23 databases (67.6%) can be linked through a personal identification number to other databases with parent–child linkage possible in 7 (21%) databases. Eight databases (23.5%) were already transformed or were in the process of being transformed into a common data model that could facilitate multidatabase studies. CONCLUSION: A Few European databases meet minimal regulatory requirements and are readily available to be used in a regulatory context. Accessibility and validity information of the included information needs to be improved. This study confirmed the fragmentation, heterogeneity and lack of transparency existing in many European EHDs.
format Online
Article
Text
id pubmed-6129090
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61290902018-09-10 Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation Pacurariu, Alexandra Plueschke, Kelly McGettigan, Patricia Morales, Daniel R Slattery, Jim Vogl, Dagmar Goedecke, Thomas Kurz, Xavier Cave, Alison BMJ Open Epidemiology OBJECTIVE: Electronic healthcare databases (EHDs) are useful tools for drug development and safety evaluation but their heterogeneity of structure, validity and access across Europe complicates the conduct of multidatabase studies. In this paper, we provide insight into available EHDs to support regulatory decisions on medicines. METHODS: EHDs were identified from publicly available information from the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance resources database, textbooks and web-based searches. Databases were selected using criteria related to accessibility, longitudinal dimension, recording of exposure and outcomes, and generalisability. Extracted information was verified with the database owners. RESULTS: A total of 34 EHDs were selected after applying key criteria relevant for regulatory purposes. The most represented regions were Northern, Central and Western Europe. The most frequent types of data source were electronic medical records (44.1%) and record linkage systems (29.4%). The median number of patients registered in the 34 data sources was 5 million (range 0.07–15 million) while the median time covered by a database was 18.5 years. Paediatric patients were included in 32 databases (94%). Completeness of information on drug exposure was variable. Published validation studies were found for only 17 databases (50%). Some level of access exists for 25 databases (73.5%), and 23 databases (67.6%) can be linked through a personal identification number to other databases with parent–child linkage possible in 7 (21%) databases. Eight databases (23.5%) were already transformed or were in the process of being transformed into a common data model that could facilitate multidatabase studies. CONCLUSION: A Few European databases meet minimal regulatory requirements and are readily available to be used in a regulatory context. Accessibility and validity information of the included information needs to be improved. This study confirmed the fragmentation, heterogeneity and lack of transparency existing in many European EHDs. BMJ Publishing Group 2018-09-05 /pmc/articles/PMC6129090/ /pubmed/30185579 http://dx.doi.org/10.1136/bmjopen-2018-023090 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Epidemiology
Pacurariu, Alexandra
Plueschke, Kelly
McGettigan, Patricia
Morales, Daniel R
Slattery, Jim
Vogl, Dagmar
Goedecke, Thomas
Kurz, Xavier
Cave, Alison
Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
title Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
title_full Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
title_fullStr Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
title_full_unstemmed Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
title_short Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
title_sort electronic healthcare databases in europe: descriptive analysis of characteristics and potential for use in medicines regulation
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129090/
https://www.ncbi.nlm.nih.gov/pubmed/30185579
http://dx.doi.org/10.1136/bmjopen-2018-023090
work_keys_str_mv AT pacurariualexandra electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT plueschkekelly electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT mcgettiganpatricia electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT moralesdanielr electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT slatteryjim electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT vogldagmar electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT goedeckethomas electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT kurzxavier electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation
AT cavealison electronichealthcaredatabasesineuropedescriptiveanalysisofcharacteristicsandpotentialforuseinmedicinesregulation